Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article describes the characteristics and management of hypertrichosis induced by low-dose oral minoxidil used for hair disorders, but reports no new clinical findings.

This review highlights that JAK inhibitors have transformed severe alopecia areata treatment by disrupting disease signaling, emphasizing the need for strategies to address non-responders and manage treatment discontinuation.

This study developed consensus guidelines for using low-dose oral and topical minoxidil in patients undergoing hair transplant surgery for pattern hair loss, recommending dosing adjustments, monitoring protocols, and timing for post-surgery application.

This study found that taking 1 mg of finasteride daily for male-pattern hair loss significantly reduces serum PSA levels, suggesting similar PSA adjustment is needed as for higher doses during prostate cancer screening.

This study reported that high-dose mizoribin therapy may be effective and safe for managing steroid-dependent pediatric systemic lupus erythematosus but requires monitoring of serum uric acid levels due to potential side effects.

Low-dose gonadotropin treatment is effective for infertility in women with PCOS, leading to high ovulation rates and comparable pregnancy rates with fewer complications.

In this case study, a 19-year-old woman with Henoch-Schönlein purpura, potentially triggered by hepatitis B vaccination, experienced improved symptoms after correcting low vitamin D levels and undergoing tonsillectomy, demonstrating these interventions may benefit similar patients.

This study reports that hair loss may be a rare side effect of levetiracetam in epilepsy patients and appears reversible upon dose reduction or cessation.

This study found variation in erythema induction across skin types, suggesting different SSR dose responses and highlighting a potential model for tailoring anti-inflammatory treatments.

This study found that vinblastine treatment rapidly increased platelet counts in childhood refractory immune thrombocytopenia, providing effective control of bleeding symptoms, although side effects like neuropathic pain were common and resolved with dose adjustments.

This review identified alopecia as a significant cosmetic side effect of antiseizure medications, particularly with valproate, lamotrigine, and carbamazepine, noting that hair loss often improves after dose adjustment.

In this retrospective study at Hiroshima University, methotrexate effectively controlled ocular inflammation in Japanese patients with non-infectious uveitis over 6 to 24 months, but a high incidence of adverse effects indicates careful monitoring and dose adjustments are important.

In this study, trilostane was generally effective and well-tolerated for treating canine Cushing's syndrome, though some dogs experienced signs of hypoadrenocorticism, and dose adjustments were necessary over time.

Low doses of oral minoxidil, a hair loss treatment, can cause temporary morning swelling around the eyes, but it's not serious and can disappear with continued use or dose adjustment.

In this study, 1 mg/day finasteride lowered serum PSA concentration in men aged 40–60, suggesting that PSA adjustment recommendations for prostate cancer screening using 5 mg/day finasteride should also apply to this lower dose for hair loss treatment.

In this study, researchers report that CDK inhibitors like palbociclib and ribociclib, initially developed for cancer therapy, show potential in treating neutrophilic inflammation-related conditions such as ARDS and psoriasis, although their clinical repurposing requires further research on safety and dose adjustments.

This study reported that while both sorafenib and lenvatinib may require dose modifications due to adverse events in treating advanced or metastatic thyroid cancers, key differences in side effect profiles were observed.

In this descriptive retrospective study, researchers reported that low-dose oral minoxidil (0.25-5mg/day) for androgenic alopecia demonstrated a good safety profile, with 84.4% of 641 patients experiencing no adverse effects and only 1.4% discontinuing due to side effects that resolved with dose reduction or withdrawal.

This systematic review reports that "COVID toes" and other skin manifestations can be initial signs of COVID-19, and advises immunosuppressive therapy adjustments only for infected or at-risk patients.

This case report of a 17-year-old with salt-wasting congenital adrenal hyperplasia due to 21-hydroxylase deficiency found that increasing the mineralocorticoid dose relieved daily headaches and reduced salt cravings.

This case report describes the successful treatment of severe bullous erythema multiforme in a patient using cyclosporine, where prior high-dose corticosteroids had only partially worked.

This study found that dermatologic adverse events are common in children taking MEK inhibitors, with selumetinib patients experiencing less severe reactions and a lower risk of dosage adjustments. Age was noted as a factor in the likelihood of specific skin reactions.

In this case study, medical management with trilostane improved clinical signs and normalized serum chemistry in a dog diagnosed with adrenal-dependent hyperadrenocorticism over 80 weeks of treatment.

This review discusses the introduction of new oral anticoagulants for atrial fibrillation and highlights their safety and the development of reversal agents, but reports no new clinical findings.

This study found that psoriasis patients on biologic therapy had significantly lower anti-COVID19 IgG antibody levels after vaccination compared to healthy individuals not on biologic treatment.

This review discusses the shift in toxicity profiles of cancer therapies from traditional chemotherapy to targeted agents, noting similar overall toxicities but with different side effects, and reports no new findings.

This study found that sorafenib was active against desmoid tumors, with 25% of patients achieving a partial response and 70% maintaining stable disease.

This paper reviews adverse events related to hedgehog pathway inhibitors in advanced basal cell carcinoma patients, reporting no new clinical results but aiming to inform healthcare professionals for improved patient care.

This review discusses managing common and notable adverse events associated with the antibody-drug conjugate trastuzumab deruxtecan in patients with HER2-positive unresectable/metastatic breast cancer and reports no new clinical results.

This article reviews the use of cross-sex hormonal therapy in transmen and reports that it is reasonably safe, suggesting monitoring should be frequent initially but can be less frequent over time.